Skip to main content
Premium Trial:

Request an Annual Quote

Frueh Leaves FDA for Medco; Kell to Lead UK's BBSRC; Marshak to Head PerkinElmer's China Operations; and Others

NEW YORK (GenomeWeb News) - Medco Health Solutions has appointed Felix Frueh to be VP of research and development, personalized medicine.
Frueh formerly was associate director for genomics at the US Food and Drug Administration’s Office of Clinical Pharmacology in the Center for Drug Evaluation and Research. He also was chair of the FDA’s Interdisciplinary Pharmacogenomics Review Group.
Prior to joining the FDA, Frueh was a managing partner at Stepoutside Consulting, research director for pharmacogenomics at Transgenomic, and an assistant director in the department of biology at Protogene Laboratories.
Before working in industry, he was an assistant professor in Georgetown University’s department of pharmacology.

Douglas Kell has been tapped as chief executive of the UK’s Biotechnology and Biological Sciences Research Council for a four-year period. 
Kell is professor of bioanalytical science at the University of Manchester, and he is director of the Manchester Centre for Integrative Systems Biology, where he will continue to work one day a week when he takes on his new position in October.

PerkinElmer has named Daniel Marshak to be president of the company’s Greater China operations. Marshak will be based out of Shangai, and he will continue to serve in his current position as the company’s senior VP and chief scientific officer.

Fred Tenover will step into the role of senior director of scientific affairs for Cepheid. He will act as a liaison with the infection-control community and he will run the company’s Healthcare Associated Infection Consortium program.
Tenover currently is distinguished consultant and director of the Office of Antimicrobial Resistance at the Centers for Disease Control and Prevention. He is also director of the CDC/World Health Organization Collaborating Center for Global Antimicrobial Resistance Monitoring, and adjunct professor in the Department of Epidemiology at Emory University’s School of Public Health.

Harold Hills has retired as director of the DNA sequencing and enzyme freezer program at the University of Massachusetts Medical School. He is a member of the Association of Biomolecular Resource Facilities.

Lee Stirling Churchman, a postdoc at the University of California, San Francisco, was recently named a Damon Runyon Fellow.
According to the Damon Runyon Cancer Research Foundation, the fellowship will support Churchman’s work examining endocytosis using quantitative RNAi-based genetic interaction maps.
“Understanding endocytosis is directly relevant to cancers involving viral entry and indirectly involved in most cancers due to its integral role in intercellular signaling,” the organization said.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.